Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07193511 · ClinicalTrials.gov registry record · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
A Phase 1 study of Urothelial Cancer and Metastatic Solid Tumors, sponsored by Avenzo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 355
- Enrollment target
- 6
- Study locations
NCT07193511 is a Phase 1 study of Urothelial Cancer and Metastatic Solid Tumors that is actively recruiting participants, run by Avenzo Therapeutics. The registered enrollment target is 355 participants, below the 560-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (37% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT07193511, a Phase 1 study of Urothelial Cancer and Metastatic Solid Tumors, is actively recruiting participants, sponsored by Avenzo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 355 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.
Conditions Studied
Interventions
- DRUG AVZO-103
- DRUG Combination Agent
Study Locations (6)
Texas
- Avenzo Therapeutics Recruiting Site - Austin
- Avenzo Therapeutics Recruiting Site - Irving
Florida
- Avenzo Therapeutics Recruiting Site - Orlando
Massachusetts
- Avenzo Therapeutics Recruiting Site - Boston
South Carolina
- Avenzo Therapeutics Recruiting Site - Myrtle Beach
Tennessee
- Avenzo Therapeutics Recruiting Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2030-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07193511
The ClinicalTrials.gov registry entry for NCT07193511 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 560-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (37% lower). The listed sponsor is Avenzo Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Urothelial Cancer appearing as the primary indexed condition, and to 2 interventions - of which AVZO-103 is the first listed.
NCT07193511 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07193511 about?
NCT07193511 is a clinical study titled "BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)". This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced o...
What is the current status of trial NCT07193511?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 355 participants. The study started on 2025-10-02. Estimated completion is 2030-09.
What conditions does trial NCT07193511 study?
This clinical trial studies the following conditions: Urothelial Cancer, Metastatic Solid Tumors, Solid Tumor Cancer, Locally Advanced.
What interventions are being tested in trial NCT07193511?
The interventions under investigation include: AVZO-103 (DRUG), Combination Agent (DRUG).
Who is sponsoring clinical trial NCT07193511?
This trial is sponsored by Avenzo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07193511 being conducted?
This trial has 6 study locations across Florida, Massachusetts, South Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
-
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RECRUITING · Phase 1
-
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
RECRUITING · Phase 1
-
SLV-154 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
ACTIVE NOT RECRUITING · Phase 1
-
A Study of ADRX-0706 in Select Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.